Magic Mushroom: Caution Is The Word

Psilocybin, the main active ingredient in magic mushrooms, is responsible for the hallucinogenic effects. In the U.S, the magic mushroom is considered a Schedule I substance, which means that it has a high potential for abuse.

In 2014, an estimated 22.9 million people in the U.S. reported lifetime use of Psilocybin, according to the Substance Abuse and Mental Health Services Administration’s National Survey on Drug Use and Health.

Recent studies have documented a wide range of positive effects of Psilocybin on the human brain, say easing depression or anxiety. But it is equally important to inform consumers about the risks associated with its use.

According to the survey data, 39% of the respondents rated acute and enduring adverse effects of Psilocybin among the top five most challenging experiences of his/her lifetime. Eleven percent put self or others at risk of physical harm during their difficult or challenging experience (i.e., a “bad trip”). There were also three cases of attempted suicide.

But, that said the rates of adverse effects after psilocybin use have been fund to be very low relative to adverse effects associated with other psychoactive drugs, according to the survey data.

RTT News

Fighting Depression with Magic Mushroom for Cancer Patients

Psilocybin—the hallucinogenic compound in so-called “magic” mushrooms—can effectively ease cancer patients’ depression and anxiety, according to a study published in the Journal of Psychopharmacology. As many as 40% of cancer patients experience depression.

A 2014 study found users of hallucinogenic mushrooms might experience more happiness. A 2015 study linked psychedelic drugs to a reduction in thoughts of suicide, and a 2016 study found psychedelic drug use was linked to lower rates of domestic violence among men with a history of substance abuse.

Participants completed interviews and questionnaires about their mood, feelings about life, and behavior before the first session, seven hours after each dose, five weeks after each dose, and six months following the final session. At the six-month mark, 80% of participants had reductions in depression and anxiety, with 60% no longer experiencing symptoms severe enough to warrant a diagnosis

Good Therapy